KONICA MINOLTA, INC. Regional anesthesia has demonstrated better post-operative analgesia, decreased opioid consumption and length of stay, early rehabilitation, fewer anesthesia-related side effects and high patient satisfaction compared to general anesthesia1,2. A joint statement from the
“Regional anesthesia delivers numerous benefits for patients, physicians and hospitals, propelling its growth as an important alternative to general anesthesia,” says
The SONIMAGE HS2 System facilitates ultrasound-guided regional anesthesia procedures with an advanced algorithm, Simple Needle Visualization (SNV®), that improves needle visibility and increases accuracy in needle placement, both for in-plane and out-of-plane approaches. SNV also adjusts the sensitivity of needle visualization depending on the type of tissue.
“Delivering best practices in regional anesthesia by creating value through innovation is a common vision uniting Medovate and Konica Minolta,” says
In addition to helping limit injectate pressure, SAFIRA also transforms regional anesthesia into a one-physician procedure by allowing a single anesthesiologist to conduct the entire procedure. Previously, an assistant was required to inject the anesthetic solution at the required pressure while the anesthesiologist inserted the needle tip using ultrasound guidance. With SAFIRA, hospitals can reduce costs associated with staffing an additional assistant for these procedures as well as potentially reduce the time per procedure by up to five minutes3.
- Cozowicz C, Poeran J, Zubizarreta N, et al. Trends in the Use of Regional Anesthesia: Neuraxial and Peripheral Nerve Blocks. Regional Anesthesia & Pain Medicine 2016;41:43-49.
- Albrecht, E. and Chin, K.J. Advances in regional anaesthesia and acute pain management: a narrative review. Anaesthesia, 2020; 75: e101-e110.
- Fong-Soe-Khioe R. Health Economic report Medovate commissioned written by a health economist from the
University of East Anglia (UEA).
About
About Medovate: www.medovate.co.uk
Medovate is a medical device company dedicated to the development and commercialisation of innovative medical technologies created within the NHS and beyond. Medovate identifies and works with high potential medtech innovations, providing the specialist management and technical resources, along with finance required to lead innovation development through clinical trials and regulatory approval. By providing funding and support at a crucial point in the development of innovative medical technologies, Medovate accelerates innovations to market in order to benefit patient care and healthcare delivery. The company has a strong portfolio relating to specialisms in anaesthesia, airway management, critical care and surgery. Medovate directly benefits the NHS by:
- Providing access to funding, support and expertise to enable innovations created within the NHS to reach the market
- Delivering commercial returns to the NHS organisations and inventors that created the technologies
Contact:
Massat Media
224.578.2388
www.konicaminolta.com/medicalusa
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/0994d419-9921-4816-b875-16719a7dd29c
https://www.globenewswire.com/NewsRoom/AttachmentNg/d3aac5a1-28e9-4648-b6b6-a3445d47fa67
Konica Minolta Healthcare SONIMAGE HS2
Simple Needle Visualization (SNV®) improves needle visibility and increases accuracy in needle placement, both for in-plane and out-of-plane approaches. SNV also adjusts the sensitivity of needle visualization depending on the type of tissue.
Medovate SAFIRA
SAFIRA (Safer Injection for Regional Anesthesia) is a new medical device designed to limit injection pressure and automatically stop injection at high pressures, helping to reduce the risk of nerve injury and improving patient safety.
2021 GlobeNewswire, Inc., source
